ColumbiaMagazine.com
Printed from:

Welcome to Columbia Magazine  
 



































 
Appalachian Regional Healthcare agrees to pay U.S.$150,000

Eastern Kentucky hospital system to pay U.S. Government $150,000 to settle allegations that it violated the Controlled Substances Act
Click on headline for complete story

From U.S. Attorney's Office
U.S. Justice Department, Eastern District of Kentucky

LEXINGTON, KY (Mon 2 Oct 2017) - Appalachian Regional Healthcare, Inc. ("ARH") has agreed to pay the United States $150,000, to settle civil allegations that it unlawfully filled fraudulent prescriptions for stimulants and that it failed to make and maintain complete and accurate records of its controlled substances, in violation of the federal Controlled Substances Act.



The settlement resolves a civil lawsuit that was filed by the United States against ARH in May of 2016. In the lawsuit, the United States alleged that Harlan ARH Hospital Pharmacy knowingly filled fraudulent prescriptions for Schedule IV stimulants. Specifically, the United States alleged that ARH knew the prescriptions were fraudulent because ARH was aware that no doctor-patient relationship existed between the Harlan ARH Emergency Room physician, who was writing the prescriptions, and the ARH nurses and staff, who were filling the prescriptions at ARH pharmacies. The lawsuit further alleged that individuals in Harlan ARH's management were made aware of the improper prescribing in 2010; yet, the Harlan ARH Hospital Pharmacy continued filling those prescriptions until 2014. The United States alleged that, as a result of these improperly filled prescriptions, ARH illegally dispensed thousands of stimulant pills to its employees and their family members.

The lawsuit further alleged that ARH failed to make and maintain complete and accurate records of its controlled substances at two other pharmacies, Hazard ARH Regional Medical Center Clinic Pharmacy and Middlesboro ARH Pharmacy, and that, because of that failure, Government auditors were prevented from being able to determine whether other controlled substances had been diverted for illegal use.

Carlton S. Shier, IV, Acting United States Attorney for the Eastern District of Kentucky and the Drug Enforcement Administration, Diversion Control Division jointly announced the settlement. The Diversion Control Division and the U.S. Attorney's Office conducted the investigation of alleged violations. Assistant U.S. Attorneys Katherine Crytzer and Daniel Hancock represented the federal government in this case.


This story was posted on 2017-10-03 15:51:18
Printable: this page is now automatically formatted for printing.
Have comments or corrections for this story? Use our contact form and let us know.



 

































 
 
Quick Links to Popular Features


Looking for a story or picture?
Try our Photo Archive or our Stories Archive for all the information that's appeared on ColumbiaMagazine.com.

 

Contact us: Columbia Magazine and columbiamagazine.com are published by Linda Waggener and Pen Waggener, PO Box 906, Columbia, KY 42728.
Phone: 270.403.0017


Please use our contact page, or send questions about technical issues with this site to webmaster@columbiamagazine.com. All logos and trademarks used on this site are property of their respective owners. All comments remain the property and responsibility of their posters, all articles and photos remain the property of their creators, and all the rest is copyright 1995-Present by Columbia Magazine. Privacy policy: use of this site requires no sharing of information. Voluntarily shared information may be published and made available to the public on this site and/or stored electronically. Anonymous submissions will be subject to additional verification. Cookies are not required to use our site. However, if you have cookies enabled in your web browser, some of our advertisers may use cookies for interest-based advertising across multiple domains. For more information about third-party advertising, visit the NAI web privacy site.